Reuters logo
Replidyne cuts 35 pct jobs, suspends development of drug
December 10, 2007 / 9:29 PM / 10 years ago

Replidyne cuts 35 pct jobs, suspends development of drug

Dec 10 (Reuters) - Biopharmaceutical company Replidyne Inc RDYN.O said it suspended the development of its topical antibiotic, codenamed REP8839, and cut about 35 percent jobs as a part of its corporate restructuring. Replidyne, which expects an expense of about $1.5 million mainly related to severance payments, said the job cuts were mostly in the administrative, clinical, regulatory and commercial functions.

The company would continue its ongoing late-stage trial for its antibiotic faropenem, which was previously rejected by U.S. regulators. (Reporting by Esha Dey in Bangalore; Editing by Gopakumar Warrier)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below